Efficacy of sorafenib therapy in patients with advanced hepatocellular carcinoma in Indian population

Abstract

Aim: Hepatocellular carcinoma (HCC) is the fourth most common type of cancer and the third leading cause of cancer-related mortality. Sorafenib is an oral multikinase inhibitor that is used for unresectable advanced HCC. It is only approved systemic therapy for advanced HCC.

Methods: A retrospective prospective study conducted in a multispeciality hospital with 50 patients who received sorafenib. The primary outcome of the study was to find out the survival rate of patients treated with sorafenib. The secondary outcome of the study was to explore the efficacy and safety of sorafenib in a progression of HCC.

Results: The median overall survival in the Indian population was found as 114 days (3.8 months) after sorafenib therapy. The efficacy of the drug sorafenib was assessed by the survival days which were based on the changes in laboratory values such as haematological and clinical biochemistry. The adverse drug reaction documented in this study was vomiting, abdominal pain; fatigue; anorexia; hyperbilirubinemia; diarrhoea; hand-foot syndrome; rash; rectal bleeding; insomnia; constipation; thrombocytopenia and abdominal discomfort.

Conclusion: Sorafenib improves the overall survival of the patients with advanced HCC in Indian population up to 3.8 months. It is a safe and effective treatment for patients with advanced HCC in Indian population. The survival of patients was found to be depended on the liver function.

Keywords

Hepatocellular carcinoma / sorafenib / Indian population

References

[1] Zhang T,Wei D,Su X,Wang D.Sorafenib improves the survival of patients with advanced hepatocellular carcinoma: a meta-analysis of randomized trials..Anticancer Drugs2010;21:326-32

[2] Kumar A,Singh SP,Arora A,Goenka MK,Kar P,Kumaran V,Panda D,Ramachandran J,Rao PN,Sharma H,The INASL Task-Force on Hepatocellular Carcinoma..The Indian National Association for Study of the Liver (INASL) Consensus on Prevention, Diagnosis and Management of Hepatocellular Carcinoma in India: The Puri Recommendations..J Clin Exp Hepatol2014;4:S3-26

[3] Davis GL,Meler JD,Walberg MW,Berger BD,Goldstein RM.Hepatocellular carcinoma: management of an increasingly common problem..Proc (Bayl Univ Med Cent).2008;21:266-80

[4] Hu H,Long X,Shi H,Yang Z.Sorafenib combined with transarterial chemoembolization versus transarterial chemoembolization alone for advanced-stage hepatocellular carcinoma: a propensity score matching study..PLoS One2014;9:e96620

[5] Nakano M,Kuromatsu R,Sakata K,Kajiwara M,Tajiri N,Sakai T,Yano Y,Kurogi J,Sumie S,Yamada S,Aino H,Torimura T.Efficacy, safety, and survival factors for sorafenib treatment in Japanese patients with advanced hepatocellular carcinoma..Oncology2013;84:108-14

[6] Xie B,Spechler SJ.Sorafenib for the treatment of hepatocellular carcinoma: a systematic review..Dig Dis Sci2012;57:1122-9 PMCID:PMC3596114

[7] Peixoto RD,Gill S,Lim HJ.Relationship of ethinity and overall survival in patients treated with sorafenib for advanced hepatocellular carcinoma..J Gastrointest Oncol2014;5:259-64

[8] Zheng SZ,Sun P,Xu YT,Liu J.Feasibility and safety of sorafenib treatment in hepatocellular carcinoma patients with spontaneous rupture..World J Gastroenterol2014;20:16275-81 PMCID:PMC4239517

[9] Abdel-Rahman O,Shaker M,Elbassiony M.Sorafenib for Egyptian patients with advanced hepatocellular carcinoma; single centre experience..J Egypt Natl Canc Inst2014;26:9-13

[10] Køstner AH,Olesen RK,Lassen U.Sorafenib in advanced hepatocellular carcinoma: a nationwide retrospective study of efficacy and tolerability..Scientific World Journal2013;2013:931-72 PMCID:PMC3569916

[11] Ji YX,Lan KT,Geng CX,Zhang L,Zou X,Zhang ZC.Sorafenib in liver function impaired advanced hepatocellular carcinoma..Chin Med Sci J2014;29:7-14

[12] Llovet JM,Mazzaferro V,Gane E,de Oliveira AC,Raoul JL,Schwartz M,Zeuzem S,Greten TF,Seitz JF,Häussinger D,Shan M,Voliotis D.Sorafenib in advanced hepatocellular carcinoma..N Engl J Med2008;359:378-90